Results 91 to 100 of about 3,564 (173)

One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis

Heliyon
Background: The 1-min sit-to-stand test (1STST) is a practical tool to evaluate physical capacity. The aim of this study was to assess the impact of tezacaftor and ivacaftor on functional exercise capacity, muscle strength and symptoms in people with ...
Aubriot Anne-Sophie, Morgane Penelle, Gonçalvès Clémence, Silvia Berardis, Christophe Goubau, Gregory Reychler, Sophie Gohy   +6 more
doaj   +1 more source

Editorial: Real-world experience with CFTR modulator therapy

Frontiers in Pharmacology, 2023
Burkhard Tümmler, Burkhard Tümmler, Pierre-Régis Burgel, Pierre-Régis Burgel   +3 more
doaj   +1 more source

Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis

JAAD Case Reports, 2021
Rebecca H. Goldberg, BS, Natalie H. Matthews, MD, MPhil, Alexandra C. Hristov, MD, Frank Wang, MD   +3 more
doaj   +1 more source

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy

, 2023
Introduction Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients,
Galoppi, Paola, Brunelli, Roberto, Ascenzioni, Fiorentina, Cimino, Giuseppe, Murciano, Manuel, Botta, Bruno, Sorrenti, Sara   +6 more
core   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

, 2019
Background Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation.
Mall, Marcus A., Moskowitz, Samuel M., Dřevínek, Pavel, Polineni, Deepika, Tullis, Elizabeth, Lands, Larry C., Tian, Simon, McKee, Charlotte M., Marigowda, Gautham, Nair, Nitin, Ramsey, Bonnie W., Van Braeckel, Eva, Middleton, Peter G., McKone, Edward F., Simard, Christopher, Waltz, David, Xuan, Fengjuan, Taylor-Cousar, Jennifer L., Savage, Jessica, Vermeulen, François, Jain, Raksha, Rowe, Steven M.   +21 more
core   +1 more source

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy

, 2022
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration.
Safirstein, Julie, Young, David C, Bourque, Brian, Diloreto, Stefanie, Antell, Martine H, Heo, Suyeon, Rotolo, Shannon M   +6 more
core  

Cystic Fibrosis: New Trends in Therapy Methods

Архивъ внутренней медицины
This review provides information on recent advancements in the treatment of cystic fi brosis and presents interim results from ongoing clinical trials. Various scientifi c databases, including Scopus, Web of Science, and EMBASE, were utilized during the ...
P. A. Suchkova, S. A. Panova, O. Ya. Lisenko, K. P. Raevskij   +3 more
doaj   +1 more source

Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice

Acta Psychologica
Recent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapies have markedly improved survival and quality of life for people with cystic fibrosis (CF).
Qian Ge, Amy Fagan, Hui Lu, Jianyang Du, Leah R. Reznikov   +4 more
doaj   +1 more source

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation

Health Technology Assessment
Background Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system ...
Steven J Edwards, Benjamin G Farrar, Kate Ennis, Nicole Downes, Victoria Wakefield, Isaac Mackenzie, Archie Walters, Tracey Jhita   +7 more
doaj   +1 more source

Efficacy of Elexacaftor–Tezacaftor–Ivacaftor on chronic rhinosinusitis in cystic fibrosis

Purpose: Our work aims to add evidence on the effectiveness of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis. Materials and methods: We conducted an observational retrospective cohort study at the Cystic Fibrosis Center ...
Molteni, Gabriele, Tommasi, Nicola, Di Gioia, Stefano, Lucca, Francesca, Venditto, Laura, Cipolli, Marco, Sandri, Giulio   +6 more
core   +1 more source